EANM指南:2-[18F]FDG PET/CT在卵巢癌诊断、分期、预后、疗效评估和再分期中的作用
该指南由EANM制定并经ACNM、SNMMI和IAEA认可,总结2-[18F]FDG PET/CT在卵巢癌各疾病阶段的临床指征证据等级和推荐级别。卵巢癌多数初诊即为晚期,约7/10患者在初诊后36个月内复发,PET/CT在原发检测、分期、预后判断尤其是复发检测方面有效,疗效评估证据有限。
要点
- 2-[18F]FDG PET/CT在卵巢癌原发检测、分期、预后判断和复发检测中有效。
- 疗效评估方面的证据有限。
- CT被认为是术前评估和分期的最佳可用技术。
核心结论
- 2-[18F]FDG PET/CT在卵巢癌原发检测、分期、预后判断尤其是复发检测方面有效,但疗效评估证据有限。
研究设计与样本
- 欧洲核医学协会(EANM)制定、经ACNM、SNMMI和IAEA认可的指南,总结各疾病阶段临床指征的证据等级和推荐级别。
主要发现
- 卵巢癌多数患者诊断时已为晚期,预后通常很差。
- 约7/10患者在初诊后36个月内出现复发。
- 卵巢癌转移播散途径包括腹膜连续播散、淋巴引流播散和血行播散。
- CT被认为是术前评估和分期的最佳可用技术。
- 2-[18F]FDG PET/CT在原发检测、分期、预后判断和复发检测方面有效,疗效评估证据有限。
临床怎么用
- 2-[18F]FDG PET/CT可用于卵巢癌原发检测、分期、预后判断和复发检测。
- 疗效评估方面证据有限,需谨慎使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In most patients with ovarian carcinoma, the diagnosis is reached when the disease is long past the initial stages, presenting already an advanced stage, and they usually have a very bad prognosis. Cytoreductive or debulking surgical procedures, platinum-based chemotherapy and targeted agents are key therapeutic elements. However, around 7 out of 10 patients present recurrent disease within 36 months from the initial diagnosis. The metastatic spread in ovarian cancer follows three pathways: contiguous dissemination across the peritoneum, dissemination through the lymphatic drainage and, although less importantly in this case, through the bloodstream. Radiological imaging, including ultrasound, CT and MRI, are the main imaging techniques in which management decisions are supported, CT being considered the best available technique for presurgical evaluation and staging purposes. Regarding 2-[18F]FDG PET/CT, the evidence available in the literature demonstrates efficacy in primary detection, disease staging and establishing the prognosis and especially for relapse detection. There is limited evidence when considering the evaluation of therapeutic response. This guideline summarizes the level of evidence and grade of recommendation for the clinical indications of 2-[18F]FDG PET/CT in each disease stage of ovarian carcinoma.
引用
- Delgado Bolton RC, Aide N, Colletti PM, et al. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging. 2021. PMID: 34215923. doi:10.1007/s00259-021-05450-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。